JP2016521279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521279A5 JP2016521279A5 JP2016512012A JP2016512012A JP2016521279A5 JP 2016521279 A5 JP2016521279 A5 JP 2016521279A5 JP 2016512012 A JP2016512012 A JP 2016512012A JP 2016512012 A JP2016512012 A JP 2016512012A JP 2016521279 A5 JP2016521279 A5 JP 2016521279A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- compared
- baseline
- reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 38
- 210000002966 serum Anatomy 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 238000008214 LDL Cholesterol Methods 0.000 claims 19
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 7
- 229950010993 atrasentan Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817645P | 2013-04-30 | 2013-04-30 | |
| US61/817,645 | 2013-04-30 | ||
| US201361824199P | 2013-05-16 | 2013-05-16 | |
| US61/824,199 | 2013-05-16 | ||
| PCT/US2014/036152 WO2014179453A1 (en) | 2013-04-30 | 2014-04-30 | Methods for improving lipid profiles using atrasentan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521279A JP2016521279A (ja) | 2016-07-21 |
| JP2016521279A5 true JP2016521279A5 (enExample) | 2017-06-15 |
Family
ID=50928265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512012A Pending JP2016521279A (ja) | 2013-04-30 | 2014-04-30 | アトラセンタンを使用して脂質プロファイルを改善するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9855245B2 (enExample) |
| EP (1) | EP2991680A1 (enExample) |
| JP (1) | JP2016521279A (enExample) |
| KR (1) | KR20160003128A (enExample) |
| CN (1) | CN105246512A (enExample) |
| AU (1) | AU2014259961A1 (enExample) |
| BR (1) | BR112015027631A2 (enExample) |
| CA (1) | CA2909871A1 (enExample) |
| HK (1) | HK1221916A1 (enExample) |
| MX (1) | MX2015015036A (enExample) |
| RU (1) | RU2015151175A (enExample) |
| SG (1) | SG11201508960SA (enExample) |
| WO (1) | WO2014179453A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101890959B1 (ko) | 2010-11-04 | 2018-08-22 | 알비레오 에이비 | 간질환 치료를 위한 ｉｂａｔ 억제제 |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN116327758A (zh) | 2019-12-17 | 2023-06-27 | 奇努克医疗公司 | 用阿曲生坦治疗IgA肾病的方法 |
| WO2021207723A2 (en) * | 2020-04-10 | 2021-10-14 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (enExample) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5544163A (en) | 1994-03-08 | 1996-08-06 | Excel, Inc. | Expandable telecommunications system |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| US20060135596A1 (en) | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| CN101822837A (zh) * | 2010-02-02 | 2010-09-08 | 王丽燕 | 包含艾力沙坦酯盐的药物组合物 |
| CA2901922A1 (en) | 2013-03-08 | 2014-09-12 | Abbvie Inc. | Methods of treating acute kidney injury |
-
2014
- 2014-04-30 JP JP2016512012A patent/JP2016521279A/ja active Pending
- 2014-04-30 KR KR1020157033693A patent/KR20160003128A/ko not_active Withdrawn
- 2014-04-30 EP EP14729532.3A patent/EP2991680A1/en not_active Withdrawn
- 2014-04-30 US US14/888,195 patent/US9855245B2/en not_active Expired - Fee Related
- 2014-04-30 SG SG11201508960SA patent/SG11201508960SA/en unknown
- 2014-04-30 MX MX2015015036A patent/MX2015015036A/es unknown
- 2014-04-30 CN CN201480032387.7A patent/CN105246512A/zh active Pending
- 2014-04-30 AU AU2014259961A patent/AU2014259961A1/en not_active Abandoned
- 2014-04-30 WO PCT/US2014/036152 patent/WO2014179453A1/en not_active Ceased
- 2014-04-30 RU RU2015151175A patent/RU2015151175A/ru not_active Application Discontinuation
- 2014-04-30 CA CA2909871A patent/CA2909871A1/en not_active Abandoned
- 2014-04-30 HK HK16110230.1A patent/HK1221916A1/zh unknown
- 2014-04-30 BR BR112015027631A patent/BR112015027631A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521279A5 (enExample) | ||
| RU2015151175A (ru) | Способы улучшения липидных профилей с применением атрасентана | |
| JP2007277267A5 (enExample) | ||
| IL274403A (en) | Tyrosine hydroxylase inhibitors for the treatment of intestinal hypertension | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| JP2017513836A5 (enExample) | ||
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2014511891A5 (enExample) | ||
| EA201400056A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| WO2012177481A3 (en) | Fibroblast growth factor receptor inhibition for the treatment of disease | |
| JP2012193216A5 (enExample) | ||
| JP2009537554A5 (enExample) | ||
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2017505285A5 (enExample) | ||
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| JP2016511753A5 (enExample) | ||
| JP2006514611A5 (enExample) | ||
| EA201291247A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН | |
| JP2012136529A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| MY181731A (en) | Azole benzene derivative | |
| CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. |